Deep6 AI has raised $30.0M in total across 1 funding round.
Deep6 AI's investors include Iaso Ventures.
Deep 6 AI is a technology company founded in 2016 that develops an AI-powered software platform to accelerate clinical trial recruitment by mining and interpreting vast amounts of structured and unstructured patient data from electronic medical records (EMRs). Its platform serves healthcare organizations, researchers, physicians, pharmaceutical sponsors, and Contract Research Organizations (CROs) by precisely matching patients to clinical trials in real time, significantly reducing the time and cost of patient recruitment and enabling faster delivery of life-saving treatments. The company’s AI-driven solution supports multiple stages of the clinical trial lifecycle, including trial design, site selection, patient recruitment, and real-world evidence generation, and is implemented enterprise-wide in healthcare systems to broaden patient access beyond individual investigators’ panels. Deep 6 AI’s technology is recognized for its ability to analyze complex clinical data such as ICD-10 codes, physician notes, pathology reports, and lab results, enhancing accuracy and efficiency in patient identification[1][2][4][5].
Deep 6 AI was founded in 2016 by Wout Brusselaers, who initially developed the AI platform for the Intelligence Community before pivoting exclusively to healthcare. Brusselaers’ background in AI and complex data environments informed the company’s focus on applying advanced AI and natural language processing (NLP) to healthcare data challenges. The idea emerged from the need to solve the notoriously slow and inefficient clinical trial recruitment process, which delays patient access to new therapies. Early traction came from partnerships with leading academic medical centers such as Cedars-Sinai Medical Center and collaborations with National Cancer Institute (NCI)-designated cancer centers, which helped validate and scale the platform. In March 2025, Deep 6 AI was acquired by Tempus, a precision medicine company, further expanding its capabilities and reach in the healthcare ecosystem[1][4][6].
Deep 6 AI rides the growing trend of applying artificial intelligence and big data analytics to healthcare, specifically targeting the inefficiencies in clinical trial recruitment—a critical bottleneck in drug development. The timing is favorable due to increasing digitization of healthcare records, regulatory encouragement for real-world evidence, and the pharmaceutical industry's urgent need to reduce trial timelines and costs. By enabling faster, more accurate patient matching and broadening access to diverse patient populations, Deep 6 AI contributes to advancing precision medicine and improving clinical trial diversity. Its integration into healthcare workflows and partnerships with major medical centers position it as a key player influencing how AI transforms clinical research and accelerates therapeutic innovation[1][4][5][6].
Looking ahead, Deep 6 AI is poised to expand its influence by scaling its platform beyond large academic medical centers to community hospitals and smaller healthcare providers, enhancing trial diversity and patient access. The acquisition by Tempus suggests deeper integration with precision medicine initiatives and broader data ecosystems, potentially enabling more personalized and efficient clinical research. Trends such as increased adoption of AI in healthcare, growing emphasis on real-world evidence, and regulatory support for innovative trial designs will shape Deep 6 AI’s trajectory. Its continued innovation in AI-driven patient matching and ecosystem building will likely solidify its role as a transformative force in clinical trials, helping bring life-saving treatments to patients faster and more equitably[1][5][6].
Deep6 AI has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $30.0M Series B | Iaso Ventures |